Vaccine-preventable influenza disease burden from clinical trials of Vaxigrip - an inactivated split virion influenza vaccine - supports wider vaccine use.
Trivalent inactivated split influenza virus vaccine has been used for more than 35 years, and is currently licensed in over 100 countries. To determine vaccine-preventable influenza burden in different populations and geographic regions, we reviewed studies of vaccine effectiveness against non-specific outcomes such as upper respiratory infection, hospitalization, and death in addition to confirmed microbiologically confirmed influenza. The vaccine-preventable disease incidence was high in most studies, regardless of the outcome or population evaluated. This indicates that routine influenza vaccination can improve overall population health under a broad range of circumstances.
Arnoux
Sabine
S
Medical Affairs International, Sanofi Pasteur, France.
Weinberger
Clement
C
Gessner
Bradford D
BD
D000914:Antibodies, Viral / Q000096:biosynthesis / Q000276:immunology; D002986:Clinical Trials as Topic; D017281:Cost of Illness; D006801:Humans; D017589:Immunization Programs; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000191:economics* / Q000276:immunology; D007251:Influenza, Human / Q000191:economics* / Q000517:prevention & control; D009975:Orthomyxoviridae / Q000276:immunology; D009976:Orthomyxoviridae Infections / Q000191:economics* / Q000276:immunology / Q000517:prevention & control / Q000821:virology; D014611:Vaccination; D015164:Vaccines, Inactivated / Q000008:administration & dosage / Q000191:economics*
D000914:Antibodies, Viral; D007252:Influenza Vaccines; D015164:Vaccines, Inactivated; C478242:vaxigrip